SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)
Completed
- Conditions
- Hepatitis A
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 614
- Registration Number
- NCT01838070
Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use
Phase 2
Completed
- Conditions
- Rabies
- Interventions
- Biological: Purified Vero Rabies Vaccine (VRVg) - Serum Free
- First Posted Date
- 2013-02-06
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 408
- Registration Number
- NCT01784874
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
Phase 2
Completed
- Conditions
- Meningococcal MeningitisInvasive Meningococcal DiseaseMeningitisMeningococcal Infections
- Interventions
- Biological: Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate VaccineBiological: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 301
- Registration Number
- NCT01732627
Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® IntradermalBiological: Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 FormulationBiological: Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 3360
- Registration Number
- NCT01712984
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
Phase 4
Completed
- Conditions
- Influenza
- Interventions
- Biological: Fluzone®; Influenza Virus Vaccine, No Preservative
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 60
- Registration Number
- NCT01691326
Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.
Phase 4
Completed
- Conditions
- Influenza
- First Posted Date
- 2012-09-24
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 200
- Registration Number
- NCT01691339
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
Phase 1
Completed
- Conditions
- TetanusDiphtheriaPertussis
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 43
- Registration Number
- NCT01689324
Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children
Completed
- Conditions
- MeningitisMeningococcal Infection
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 116
- Registration Number
- NCT01689155
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age
Phase 4
Completed
- Conditions
- Meningococcal InfectionMeningitisDiphtheriaTetanusPertussisHaemophilus Influenzae Serotype b (Hib)
- Interventions
- Biological: Meningococcal polysaccharide diphtheria toxoid conjugateBiological: Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis AdsorbedBiological: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 1394
- Registration Number
- NCT01659996
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea
Phase 3
Completed
- Conditions
- MeningitisMeningococcal Disease
- Interventions
- Biological: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- First Posted Date
- 2012-07-17
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT01642589
© Copyright 2025. All Rights Reserved by MedPath